Cargando…

Tianxiangdan Improves Coronary Microvascular Dysfunction in Rats by Inhibiting Microvascular Inflammation via Nrf2 Activation

BACKGROUND: Tianxiangdan (TXD) is used in traditional Chinese medicine because of its therapeutic and preventive effects in the treatment of coronary heart disease. However, the underlying mechanism of TXD in coronary microvascular disease (CMD) remains unclear. METHODS: A rat model of CMD was devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawuer, Guligena, Ma, Xue-Kuan, Zhang, Ya-Jie, Zhang, Xuan-Ming, Ainiwaer, Zulihumaer, An, Dong-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660204/
https://www.ncbi.nlm.nih.gov/pubmed/34899948
http://dx.doi.org/10.1155/2021/4114784
_version_ 1784613139619250176
author Sawuer, Guligena
Ma, Xue-Kuan
Zhang, Ya-Jie
Zhang, Xuan-Ming
Ainiwaer, Zulihumaer
An, Dong-Qing
author_facet Sawuer, Guligena
Ma, Xue-Kuan
Zhang, Ya-Jie
Zhang, Xuan-Ming
Ainiwaer, Zulihumaer
An, Dong-Qing
author_sort Sawuer, Guligena
collection PubMed
description BACKGROUND: Tianxiangdan (TXD) is used in traditional Chinese medicine because of its therapeutic and preventive effects in the treatment of coronary heart disease. However, the underlying mechanism of TXD in coronary microvascular disease (CMD) remains unclear. METHODS: A rat model of CMD was developed to study the mechanism of TXD activity. Sodium laurate was injected into the left ventricle of Sprague–Dawley rats to induce CMD. The rats were divided into six groups: a sham-operated (sham) group, an untreated CMD group, a low-dose TXD group (0.81 g·kg(−1)·d(−1)), a mid-dose TXD (TXD-M) group (1.62 g·kg(−1)·d(−1)), a high-dose TXD (TXD-H) group (3.24 g·kg(−1)·d(−1)), and a nicorandil (NCR) group (1.35 mg·kg(−1)·d(−1)). The effect of TXD on rats with CMD was observed after four weeks, and the mechanism of TXD in lipopolysaccharide (LPS)-induced cardiac microvascular endothelial cells (CMECs) was explored through treatment with 50 μg/mL TXD. RESULTS: Compared with the rats in the untreated CMD group, rats in the TXD-M and TXD-H groups showed higher left ventricular ejection fraction values, improved pathological structures, decreased expressions of interleukin (IL)-1β, tumor necrosis factor-alpha (TNF-α), phosphorylated nuclear factor-κB inhibitor α (IκBα) and phosphorylated p65, and increased expressions of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (P < 0.05). These effects were more pronounced in the TXD-H group than in the TXD-M group. In vitro experiments showed that TXD treatment increased the viability of LPS-induced CMECs and decreased the expression of IL-1β, TNF-α, phosphorylated IκBα, and phosphorylated p65 (P < 0.05). However, the effects of TXD on CMECs were markedly reversed upon treatment with ML385 (Nrf2 inhibitor). CONCLUSION: The results showed that TXD exerts a protective effect on rats with CMD and related inflammatory injuries, and its anti-inflammatory mechanism is related to the activation of Nrf2 signalling.
format Online
Article
Text
id pubmed-8660204
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-86602042021-12-10 Tianxiangdan Improves Coronary Microvascular Dysfunction in Rats by Inhibiting Microvascular Inflammation via Nrf2 Activation Sawuer, Guligena Ma, Xue-Kuan Zhang, Ya-Jie Zhang, Xuan-Ming Ainiwaer, Zulihumaer An, Dong-Qing Evid Based Complement Alternat Med Research Article BACKGROUND: Tianxiangdan (TXD) is used in traditional Chinese medicine because of its therapeutic and preventive effects in the treatment of coronary heart disease. However, the underlying mechanism of TXD in coronary microvascular disease (CMD) remains unclear. METHODS: A rat model of CMD was developed to study the mechanism of TXD activity. Sodium laurate was injected into the left ventricle of Sprague–Dawley rats to induce CMD. The rats were divided into six groups: a sham-operated (sham) group, an untreated CMD group, a low-dose TXD group (0.81 g·kg(−1)·d(−1)), a mid-dose TXD (TXD-M) group (1.62 g·kg(−1)·d(−1)), a high-dose TXD (TXD-H) group (3.24 g·kg(−1)·d(−1)), and a nicorandil (NCR) group (1.35 mg·kg(−1)·d(−1)). The effect of TXD on rats with CMD was observed after four weeks, and the mechanism of TXD in lipopolysaccharide (LPS)-induced cardiac microvascular endothelial cells (CMECs) was explored through treatment with 50 μg/mL TXD. RESULTS: Compared with the rats in the untreated CMD group, rats in the TXD-M and TXD-H groups showed higher left ventricular ejection fraction values, improved pathological structures, decreased expressions of interleukin (IL)-1β, tumor necrosis factor-alpha (TNF-α), phosphorylated nuclear factor-κB inhibitor α (IκBα) and phosphorylated p65, and increased expressions of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (P < 0.05). These effects were more pronounced in the TXD-H group than in the TXD-M group. In vitro experiments showed that TXD treatment increased the viability of LPS-induced CMECs and decreased the expression of IL-1β, TNF-α, phosphorylated IκBα, and phosphorylated p65 (P < 0.05). However, the effects of TXD on CMECs were markedly reversed upon treatment with ML385 (Nrf2 inhibitor). CONCLUSION: The results showed that TXD exerts a protective effect on rats with CMD and related inflammatory injuries, and its anti-inflammatory mechanism is related to the activation of Nrf2 signalling. Hindawi 2021-12-02 /pmc/articles/PMC8660204/ /pubmed/34899948 http://dx.doi.org/10.1155/2021/4114784 Text en Copyright © 2021 Guligena Sawuer et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sawuer, Guligena
Ma, Xue-Kuan
Zhang, Ya-Jie
Zhang, Xuan-Ming
Ainiwaer, Zulihumaer
An, Dong-Qing
Tianxiangdan Improves Coronary Microvascular Dysfunction in Rats by Inhibiting Microvascular Inflammation via Nrf2 Activation
title Tianxiangdan Improves Coronary Microvascular Dysfunction in Rats by Inhibiting Microvascular Inflammation via Nrf2 Activation
title_full Tianxiangdan Improves Coronary Microvascular Dysfunction in Rats by Inhibiting Microvascular Inflammation via Nrf2 Activation
title_fullStr Tianxiangdan Improves Coronary Microvascular Dysfunction in Rats by Inhibiting Microvascular Inflammation via Nrf2 Activation
title_full_unstemmed Tianxiangdan Improves Coronary Microvascular Dysfunction in Rats by Inhibiting Microvascular Inflammation via Nrf2 Activation
title_short Tianxiangdan Improves Coronary Microvascular Dysfunction in Rats by Inhibiting Microvascular Inflammation via Nrf2 Activation
title_sort tianxiangdan improves coronary microvascular dysfunction in rats by inhibiting microvascular inflammation via nrf2 activation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660204/
https://www.ncbi.nlm.nih.gov/pubmed/34899948
http://dx.doi.org/10.1155/2021/4114784
work_keys_str_mv AT sawuerguligena tianxiangdanimprovescoronarymicrovasculardysfunctioninratsbyinhibitingmicrovascularinflammationvianrf2activation
AT maxuekuan tianxiangdanimprovescoronarymicrovasculardysfunctioninratsbyinhibitingmicrovascularinflammationvianrf2activation
AT zhangyajie tianxiangdanimprovescoronarymicrovasculardysfunctioninratsbyinhibitingmicrovascularinflammationvianrf2activation
AT zhangxuanming tianxiangdanimprovescoronarymicrovasculardysfunctioninratsbyinhibitingmicrovascularinflammationvianrf2activation
AT ainiwaerzulihumaer tianxiangdanimprovescoronarymicrovasculardysfunctioninratsbyinhibitingmicrovascularinflammationvianrf2activation
AT andongqing tianxiangdanimprovescoronarymicrovasculardysfunctioninratsbyinhibitingmicrovascularinflammationvianrf2activation